Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis (NCT05006430) | Clinical Trial Compass
RecruitingPhase 1/2
Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis
United States50 participantsStarted 2023-01-21
Plain-language summary
This is a single center, randomized, parallel assignment, and double-blind placebo-controlled pilot study to characterize the intestinal microbiome in patients with severe Alcoholic Hepatitis (SAH) and evaluate the safety and the trends in improvement of diversity of intestinal microbiome following administration of lyophilized capsules containing microbiota suspension from well screened health donors. The study aims to enroll 50 patients with SAH who will be randomly assigned in 1:1 where 25 patients will be assigned to receive orally administered lyophilized PRIM-DJ2727 and Standard of Care (SOC) and the other 25 patients will be assigned to receive placebo and SOC for 4 weeks.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Any gender; male or female; aged 18- 75 years old.
✓. Severe alcoholic hepatitis defined as 2.1 Onset of jaundice within prior 8 weeks. 2.2 Ongoing alcohol consumption of \>40 g/day (3 drinks) in females or \>60 g/day (4 drinks) in males for 6 months or more, with less than 60 days of abstinence before the onset of jaundice. 2.3 Aspartate aminotransferase \>50, Aspartate aminotransferase/Alanine aminotransferase ratio \> 1.5, BUT both values \<400 IU/L.
✓.4 Serum total bilirubin \>3.0 mg/dl. 2.5 MELD score \>15 and/or Maddrey DF score of ≥32.
Exclusion criteria
✕. Non-alcoholic related liver diseases.
✕. Patients with swallowing dysfunction at risk of aspiration.
✕. Patients at risk for or with known anatomic or functional gastrointestinal (GI) obstruction or who have undergone major intra-abdominal surgery in the last year.
✕. Patients who have undergone placement of a portosystemic shunt, infection of which may require prolonged antibiotics.
✕
What they're measuring
1
To Assess survival in patients with severe alcoholic hepatitis receiving PRIM-DJ2727 capsules in comparison to standard of care.
Timeframe: [Day1 to 12 month]
2
To assess the change in gut microbiome population associated with severe alcoholic hepatitis patients from baseline in study population at 4 weeks.
Timeframe: At [Baseline] [4 weeks]
3
To assess the change in gut microbiome population associated with severe alcoholic hepatitis patients from baseline in study population at 6 months.
Timeframe: At [Baseline] [6 months]
4
To assess the change in gut microbiome population associated with severe alcoholic hepatitis patients from baseline in study population at 9 months.
Timeframe: At [Baseline] [9 months]
5
To assess the change in gut microbiome population associated with severe alcoholic hepatitis patients from baseline in study population at 12 months.
. Patients with any congenital or acquired immunodeficiency (Other than liver disease)
✕. Uncontrolled infections, sepsis, or GI bleeding.
✕. Presence of cancer especially patients with skin cancer who is receiving or may receive systemic chemotherapy or immunotherapy during the study period.
✕. Underlying disease that might be exacerbated by proposed treatments (e.g. HCV, HBV, HIV, TB).